Last updated: 2026-09-08 22:21:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Erasca, Inc. (ERAS) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $16.29, with a market capitalization of $5.66B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.53 to $24.28. This page covers its latest market performance, valuation, price trends and company information.
$5.66B | |
$15.88 | |
$24.47 | |
$1.01 | |
$16.19 | |
3.54M | |
4.56M | |
-- | |
$24.28 | |
$1.53 | |
-- | |
-- |
Erasca, Inc. (ERAS) is trading at $16.70 in after-hours trading as of 2026-09-08 22:08:00, up 3.15% ($0.51) from the regular-session close of $16.19.
After-hours trading shows how investors are pricing ERAS after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Erasca, Inc. (ERAS) moved from $19.49 to $16.29, representing a decline of 16.44% ($3.20).
The stock traded between $15.74 and $20.40 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 4.20 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 64.9%
ERAS is currently trading at $16.29, placing it 64.9% of the way from its 52-week low of $1.53 to its 52-week high of $24.28. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 103 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Erasca, Inc. (ERAS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.